Mass Spectroscopy as a Discovery Tool for Identifying Serum Markers for Prostate Cancer

Open Access
Publisher Website
Google Scholar
Abstract
Prostate cancer is the second most common malignancy in men, after skin cancer, and the second most common cause of cancer death in men over age 60 years, after lung cancer. This year, ∼198 100 new cases of prostate cancer will be diagnosed in the US, and an estimated 31 500 men will die of prostate cancer (1). Five-year survival is close to 100% when the disease is diagnosed and treated with definitive local therapy while it is still organ-confined, but in approximately one-third of men diagnosed with clinically localized disease, the disease has spread beyond the confines of the prostate at the time of surgery (2)(3).